Physician profile
John Mauro
NPI 1336315753
$6,420.23
in general payments reported to CMS, 2019-2025
23 companies · $991 in 2025
The $991 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $248 · 2021: $769 · 2022: $1,192 · 2023: $1,627 · 2024: $1,175 · 2025: $991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,774 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,774.37 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,791.21 | 2019-2025 | Clareon, Tryptyr, Eysuvis |
| Oyster Point Pharma, INC. | $838.79 | 2022-2024 | Tyrvaya |
| Abbvie INC. | $770.68 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $403.07 | 2019-2022 | |
| Rxsight INC | $386.40 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Harrow Eye, LLC | $357.56 | 2024-2025 | Vevye |
| Ocular Therapeutix, INC. | $293.65 | 2022-2023 | Dextenza |
| Bausch & Lomb Americas INC. | $274.21 | 2023-2025 | Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $224.85 | 2019-2025 | Cequa |
| Kala Pharmaceuticals, INC. | $166.75 | 2019-2021 | |
| Allergan, INC. | $150.06 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $146.49 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $125.00 | 2025 | Oxervate |
| Glaukos Corporation | $123.19 | 2021 | |
| Shire North American Group INC | $91.94 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $57.39 | 2023 | |
| Apellis Pharmaceuticals, INC. | $52.28 | 2025 | Syfovre |
| Eyevance Pharmaceuticals LLC | $50.84 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $44.76 | 2019-2020 | |
| Beaver-Visitec International, INC. | $20.45 | 2023 | |
| Genentech USA, INC. | $18.57 | 2021 | |
| Alimera Sciences, INC. | $16.93 | 2022 | |
| Sight Sciences, INC. | $15.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mauro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.